{"id":749290,"date":"2023-04-19T16:36:00","date_gmt":"2023-04-19T20:36:00","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/viracta-therapeutics-to-present-at-the-stifel-2023-targeted-oncology-days\/"},"modified":"2023-04-19T16:36:00","modified_gmt":"2023-04-19T20:36:00","slug":"viracta-therapeutics-to-present-at-the-stifel-2023-targeted-oncology-days","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/viracta-therapeutics-to-present-at-the-stifel-2023-targeted-oncology-days\/","title":{"rendered":"Viracta Therapeutics to Present at the Stifel 2023 Targeted Oncology Days"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">SAN DIEGO, April  19, 2023  (GLOBE NEWSWIRE) &#8212; Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced that Mark Rothera, its President and Chief Executive Officer, and Lisa Rojkjaer, M.D., its Chief Medical Officer, are scheduled to participate in a virtual fireside chat at the Stifel 2023 Targeted Oncology Days on Wednesday, April 26, 2023, at 12:00 p.m. ET.<\/p>\n<p align=\"justify\">A live webcast of the fireside chat will be available on the Investors section of the Viracta website under &#8220;<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=YKlEG6B63jeRfvVys85hRsDqDYnHOeHDqC1iRmVwxcEa0VRjnkhVvQo76w6v5LYLqIimCd2T5oelkpKfqYEA41qOkqn3jDqqql6tjiS3GaN2XUhZ4sHTIF02xrUmzYLl\" rel=\"nofollow noopener\" target=\"_blank\">Events and Webcasts<\/a>&#8221; and archived for 90 days.<\/p>\n<p align=\"justify\">\n        <strong>About Viracta Therapeutics, Inc.<\/strong>\n      <\/p>\n<p align=\"justify\">Viracta is a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide. Viracta\u2019s lead product candidate is an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir (collectively referred to as Nana-val). Nana-val is currently being evaluated in multiple ongoing clinical trials, including a pivotal, global, multicenter, open-label Phase 2 basket trial for the treatment of multiple subtypes of relapsed\/refractory Epstein-Barr virus-positive (EBV<sup>+<\/sup>) lymphoma (NAVAL-1), as well as a multinational, open-label Phase 1b\/2 trial for the treatment of EBV<sup>+<\/sup>\u00a0recurrent or metastatic nasopharyngeal carcinoma and other EBV<sup>+<\/sup>\u00a0solid tumors. Viracta is also pursuing the application of its \u201c<em>Kick and Kill\u201d<\/em>\u00a0approach in other virus-related cancers.<\/p>\n<p align=\"justify\">For additional information please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=mKpNqlbapqIltMXhkWpWWNhqBThqEweGoDdYCy8IqnBLHI83ug4E6hzja1auCx0WQuatM6IQ2Gh_8drgg9NRcQ==\" rel=\"nofollow noopener\" target=\"_blank\">www.viracta.com<\/a>.<\/p>\n<p>\n        <strong>Investor Relations Contact:<\/strong><br \/>\n        <br \/>Ashleigh Barreto<br \/>Head of Investor Relations &amp; Corporate Communications<br \/>Viracta Therapeutics, Inc.<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=xnE0gEa3yax0-LQd_D-hZm7TFF6c4ZKUpFNCMgjskitfBdQ2FPnQf5L9FpX7Bc-Ys1Sbl81m6t9LHd8rF-jz-R7aano-ziD92YRgYe4gito=\" rel=\"nofollow noopener\" target=\"_blank\">abarreto@viracta.com<\/a><\/p>\n<p>SOURCE Viracta Therapeutics, Inc.<\/p>\n<p \/>\n      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgxMTU2MSM1NTM2NDEwIzUwMDEwOTIxNw==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/MTExNjgzYzYtNzI5Zi00OTk0LWJlNzgtMGRlNjVmNGEwMWZiLTUwMDEwOTIxNw==\/tiny\/Viracta-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SAN DIEGO, April 19, 2023 (GLOBE NEWSWIRE) &#8212; Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced that Mark Rothera, its President and Chief Executive Officer, and Lisa Rojkjaer, M.D., its Chief Medical Officer, are scheduled to participate in a virtual fireside chat at the Stifel 2023 Targeted Oncology Days on Wednesday, April 26, 2023, at 12:00 p.m. ET. A live webcast of the fireside chat will be available on the Investors section of the Viracta website under &#8220;Events and Webcasts&#8221; and archived for 90 days. About Viracta Therapeutics, Inc. Viracta is a precision oncology company focused on the treatment and prevention of virus-associated cancers &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/viracta-therapeutics-to-present-at-the-stifel-2023-targeted-oncology-days\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Viracta Therapeutics to Present at the Stifel 2023 Targeted Oncology Days&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-749290","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Viracta Therapeutics to Present at the Stifel 2023 Targeted Oncology Days - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/viracta-therapeutics-to-present-at-the-stifel-2023-targeted-oncology-days\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Viracta Therapeutics to Present at the Stifel 2023 Targeted Oncology Days - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SAN DIEGO, April 19, 2023 (GLOBE NEWSWIRE) &#8212; Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced that Mark Rothera, its President and Chief Executive Officer, and Lisa Rojkjaer, M.D., its Chief Medical Officer, are scheduled to participate in a virtual fireside chat at the Stifel 2023 Targeted Oncology Days on Wednesday, April 26, 2023, at 12:00 p.m. ET. A live webcast of the fireside chat will be available on the Investors section of the Viracta website under &#8220;Events and Webcasts&#8221; and archived for 90 days. About Viracta Therapeutics, Inc. Viracta is a precision oncology company focused on the treatment and prevention of virus-associated cancers &hellip; Continue reading &quot;Viracta Therapeutics to Present at the Stifel 2023 Targeted Oncology Days&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/viracta-therapeutics-to-present-at-the-stifel-2023-targeted-oncology-days\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-19T20:36:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgxMTU2MSM1NTM2NDEwIzUwMDEwOTIxNw==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/viracta-therapeutics-to-present-at-the-stifel-2023-targeted-oncology-days\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/viracta-therapeutics-to-present-at-the-stifel-2023-targeted-oncology-days\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Viracta Therapeutics to Present at the Stifel 2023 Targeted Oncology Days\",\"datePublished\":\"2023-04-19T20:36:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/viracta-therapeutics-to-present-at-the-stifel-2023-targeted-oncology-days\\\/\"},\"wordCount\":256,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/viracta-therapeutics-to-present-at-the-stifel-2023-targeted-oncology-days\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgxMTU2MSM1NTM2NDEwIzUwMDEwOTIxNw==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/viracta-therapeutics-to-present-at-the-stifel-2023-targeted-oncology-days\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/viracta-therapeutics-to-present-at-the-stifel-2023-targeted-oncology-days\\\/\",\"name\":\"Viracta Therapeutics to Present at the Stifel 2023 Targeted Oncology Days - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/viracta-therapeutics-to-present-at-the-stifel-2023-targeted-oncology-days\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/viracta-therapeutics-to-present-at-the-stifel-2023-targeted-oncology-days\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgxMTU2MSM1NTM2NDEwIzUwMDEwOTIxNw==\",\"datePublished\":\"2023-04-19T20:36:00+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/viracta-therapeutics-to-present-at-the-stifel-2023-targeted-oncology-days\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/viracta-therapeutics-to-present-at-the-stifel-2023-targeted-oncology-days\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/viracta-therapeutics-to-present-at-the-stifel-2023-targeted-oncology-days\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgxMTU2MSM1NTM2NDEwIzUwMDEwOTIxNw==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgxMTU2MSM1NTM2NDEwIzUwMDEwOTIxNw==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/viracta-therapeutics-to-present-at-the-stifel-2023-targeted-oncology-days\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Viracta Therapeutics to Present at the Stifel 2023 Targeted Oncology Days\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Viracta Therapeutics to Present at the Stifel 2023 Targeted Oncology Days - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/viracta-therapeutics-to-present-at-the-stifel-2023-targeted-oncology-days\/","og_locale":"en_US","og_type":"article","og_title":"Viracta Therapeutics to Present at the Stifel 2023 Targeted Oncology Days - Market Newsdesk","og_description":"SAN DIEGO, April 19, 2023 (GLOBE NEWSWIRE) &#8212; Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced that Mark Rothera, its President and Chief Executive Officer, and Lisa Rojkjaer, M.D., its Chief Medical Officer, are scheduled to participate in a virtual fireside chat at the Stifel 2023 Targeted Oncology Days on Wednesday, April 26, 2023, at 12:00 p.m. ET. A live webcast of the fireside chat will be available on the Investors section of the Viracta website under &#8220;Events and Webcasts&#8221; and archived for 90 days. About Viracta Therapeutics, Inc. Viracta is a precision oncology company focused on the treatment and prevention of virus-associated cancers &hellip; Continue reading \"Viracta Therapeutics to Present at the Stifel 2023 Targeted Oncology Days\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/viracta-therapeutics-to-present-at-the-stifel-2023-targeted-oncology-days\/","og_site_name":"Market Newsdesk","article_published_time":"2023-04-19T20:36:00+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgxMTU2MSM1NTM2NDEwIzUwMDEwOTIxNw==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/viracta-therapeutics-to-present-at-the-stifel-2023-targeted-oncology-days\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/viracta-therapeutics-to-present-at-the-stifel-2023-targeted-oncology-days\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Viracta Therapeutics to Present at the Stifel 2023 Targeted Oncology Days","datePublished":"2023-04-19T20:36:00+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/viracta-therapeutics-to-present-at-the-stifel-2023-targeted-oncology-days\/"},"wordCount":256,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/viracta-therapeutics-to-present-at-the-stifel-2023-targeted-oncology-days\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgxMTU2MSM1NTM2NDEwIzUwMDEwOTIxNw==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/viracta-therapeutics-to-present-at-the-stifel-2023-targeted-oncology-days\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/viracta-therapeutics-to-present-at-the-stifel-2023-targeted-oncology-days\/","name":"Viracta Therapeutics to Present at the Stifel 2023 Targeted Oncology Days - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/viracta-therapeutics-to-present-at-the-stifel-2023-targeted-oncology-days\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/viracta-therapeutics-to-present-at-the-stifel-2023-targeted-oncology-days\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgxMTU2MSM1NTM2NDEwIzUwMDEwOTIxNw==","datePublished":"2023-04-19T20:36:00+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/viracta-therapeutics-to-present-at-the-stifel-2023-targeted-oncology-days\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/viracta-therapeutics-to-present-at-the-stifel-2023-targeted-oncology-days\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/viracta-therapeutics-to-present-at-the-stifel-2023-targeted-oncology-days\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgxMTU2MSM1NTM2NDEwIzUwMDEwOTIxNw==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgxMTU2MSM1NTM2NDEwIzUwMDEwOTIxNw=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/viracta-therapeutics-to-present-at-the-stifel-2023-targeted-oncology-days\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Viracta Therapeutics to Present at the Stifel 2023 Targeted Oncology Days"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/749290","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=749290"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/749290\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=749290"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=749290"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=749290"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}